Remogliflozin Etabonate Hydrate is a potent sodium-glucose cotransporter-2 (SGLT2) inhibitor used in the management of Type 2 Diabetes Mellitus to improve glycemic control by reducing renal glucose reabsorption.… Read more
Remogliflozin Etabonate Hydrate is a potent sodium-glucose cotransporter-2 (SGLT2) inhibitor used in the management of Type 2 Diabetes Mellitus to improve glycemic control by reducing renal glucose reabsorption. This category features high-quality reference standards essential for comprehensive pharmaceutical analysis, including pharmacopeial and non-pharmacopeial impurities, degradation products, and metabolites. These compounds are critical for impurity profiling, method validation, and rigorous quality control testing required during drug development and regulatory submissions. Additionally, stable isotope-labelled versions of Remogliflozin Etabonate Hydrate are available to facilitate precise quantitative bioanalysis and support pharmacokinetic studies. Pharmaceutical laboratories rely on these specialized materials to ensure accurate identification and quantification of compounds, supporting the integrity of analytical workflows and adherence to stringent industry standards throughout the lifecycle of the drug product.